Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

doi:10.1016/j.neo.2020.07.003

Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma

Christopher S. Koivisto & Gustavo Leone et al. · 2020-08-17

Androgen Receptor (AR) signaling is a critical driver of hormone-dependent prostate cancer and has also been proposed to have biological activity in female hormone-dependent cancers, including type I endometrial carcinoma (EMC). In this study, we evaluated the preclinical efficacy of a third-generation AR antagonist, enzalutamide, in a genetic mouse model of EMC, Sprr2f-Cre;Pten

Links

DOI PubMed

Journal

Neoplasia

Authors

Christopher S. Koivisto, Melodie Parrish, Santosh B. Bonala, Soo Ngoi, Adrian Torres, James Gallagher, Rebekah Sanchez-Hodge, Victor Zeinner, Georges J. Nahhas, Bei Liu, David E. Cohn, Floor J. Backes, Paul J. Goodfellow, Helen M. Chamberlin, Gustavo Leone

Funding

MUSC Digestive Disease Research Core Center Tumor suppressor roles of E2F7 & E2F8 in hepatocellular carcinoma Medical University of South Carolina - Cancer Center Support Grant Tumor suppressor roles of E2F7 & E2F8 in hepatocellular carcinoma National Institutes of Health Grant NCCNENZA0015 Medical University of South Carolina - Cancer Center Support Grant National Cancer Institute Funding

NIDDK NIH HHS

P30 DK123704

NCI NIH HHS

R01 CA121275

NCI NIH HHS

P30 CA138313

National Institutes of Health

R01CA121275

Medical University of South Carolina

P30 CA138313